Management Team

Hal Gunn, MD
CEO

Hal Gunn, MD, founder and CEO of Qu Biologics, is a physician-entrepreneur who has dedicated his professional life to understanding how to optimally support the body’s innate immune capacity to heal. Dr. Gunn is recognized both nationally and internationally as a leader in the field of supportive oncology, and in 2009 was awarded the $250,000 Dr. Roger’s Prize for vision, leadership and integrity in the field of Integrative Medicine.

In 1997, Dr. Gunn co-founded InspireHealth, Canada’s foremost supportive cancer care centre, to support the health, healing and immune system function of people undergoing cancer treatment and their families. Under Dr. Gunn’s leadership, InspireHealth grew to become a world leader in supportive cancer care, with three centres treating 2,500 new patients per year, funded by the provincial government.

In 2007, Dr. Gunn founded Qu Biologics to develop his discovery of potentially transformative platform that restores innate immunity, and all the important cells and roles of innate immunity, in a targeted organ. Dr. Gunn obtained his Doctorate of Medicine from the University of British Columbia (UBC) and remains a Clinical Assistant Professor at UBC’s School of Medicine.

Rod Campbell, MBA
Chief Financial Officer

Rod has been managing partner at VRG Capital Corp., and independent private equity firm, since 2014. In 2019 Rod led two exceptionally successful exits in the insurance industry for VRG. As CEO of Jones Brown Inc., a retail property/casualty insurance broker, Rod facilitated a sale to Arthur J. Gallagher & Co, a global insurance brokerage, risk management and consulting firm.  The second transaction was as Chairman of Apri Insurance Corp, a leading group benefits consulting firm in Canada. In November of 2019, Apri was acquired by People Corporation a national provider of group benefits, group retirement and human resource services. 

Prior to leading investments in insurance, Rod was at Clarus Securities Inc. for 10 years, one of Canada’s leading independent investment banks. While Rod was leading the investment banking team, Clarus participated in transactions with a value in excess of $10 billion. Rod left Clarus as CEO in 2013.  Early in his career, Rod spent a decade at CIBC and has an MBA from the University of British Columbia.

 

pick2

Simon Sutcliffe, MD, FRCP, FRCPC, FRCR
Chief Medical Officer

Dr. Sutcliffe is a distinguished clinician, scientist and leading visionary in cancer control in Canada and internationally. A graduate of St. Bartholomew’s Hospital, London, England, Dr. Sutcliffe’s training encompassed internal medicine, scientific research, medical and radiation oncology in the UK, South Africa, US and Canada. He has published extensively in the areas of radiation and medical oncology as applied to the treatment of lymphoma, leukemia and cellular immuno-deficiency and immuno-modulation in cancer.

Dr. Sutcliffe has been President and CEO of the Ontario Cancer Institute and Princess Margaret Hospital (1994-96) and the BC Cancer Agency (2000-09). Dr. Sutcliffe was the inaugural Chair of the Governing Council of the Canadian Strategy for Cancer Control, a past member of the NCIC Board of Directors, and past chair of the Canadian Partnership against Cancer, the Canadian Cancer Society/National Cancer Institute of Canada Joint Advisory Committee on Cancer Control and the National Medical Advisory Committee. He has also served on the boards of the Michael Smith Foundation for Health Research and Genome BC.

Dr. Sutcliffe is currently the President of the International Cancer Control Congress Association, President of Two Worlds Cancer Collaboration (the Canadian Branch of the International Network for Cancer Treatment and Research) and the CEO of Premier Diagnostic Centre. He serves on the boards of Premier Diversified Holdings, Premier Diagnostic Centre and InspireHealth, and is Past Chair of the Canadian Partnership against Cancer and the Institute for Health Systems Transformation & Sustainability. He is a past senior advisor to the Terry Fox Research Institute. Dr. Sutcliffe was awarded the Queen Elizabeth 50th Jubilee Gold Medal in 2003 and the Terry Fox Award (of the B.C. Medical Association) in 2009 for his lifetime services to cancer control.

 

Alun Rees BSc
Vice President, CMC

Mr Rees is the Vice President of Manufacturing at Qu Biologics. He has more than 30 years experience of cGMP manufacturing and Technical Operations covering North America, Europe and Asia in both the Biotechnology and Biopharmaceutical Industries. Mr Rees has been directly responsible for managing facilities that manufacture both clinical and commercial liquid and lyophilized parenteral products that have been successfully inspected by FDA, HPFB, EMA and MHRA. He has also managed the successful technical transfer of drug substance and sterile drug products to 3rd party contract manufacturing organizations. He has most recently been the Director of Manufacturing at STEMCELL Technologies Canada Inc and the Director of Product Operations at QLT Inc in Vancouver. Before relocating to Canada in 2002, Mr Rees held management positions at both GSK and Bio Products Laboratory in the UK in the manufacture of therapeutic proteins from human deep cell culture and donated blood plasma fractionation. Mr Rees holds a BSc (Hons) in Natural Sciences with Biology from the Open University in the UK.

Jim Pankovich Qu web

Jim Pankovich, MSc, MBA
Vice President, Clinical Operations & Drug Development

Mr. Pankovich has more than 25 years of experience in the biopharmaceutical industry with extensive strategy development, clinical study management and operational experience. During his career, he has guided the development of novel compounds and biologics for the treatment of various cancers and infectious disease in all phases of clinical development from concept to NDA filing. Most recently he served as the Chief Scientific Officer of the CIHR Canadian HIV Trials Network. He was formerly the Senior Director, Clinical Research for MIGENIX Inc, Associate Director, Clinical Research at Inex Pharmaceuticals, and Vice President, Operations & Clinical Research at CV Technologies. Mr. Pankovich holds a M.Sc. (Experimental Medicine) from the University of Alberta and an MBA from Queen’s University.

Shirin Kalyan, PhD
Vice President, Scientific Innovation

Dr. Shirin Kalyan is a translational immunologist and Faculty Member in the Department of Medicine at the University of British Columbia. She earned her PhD in Experimental Medicine investigating the pivotal immune mediators of inflammation in toxic shock syndrome. Dr. Kalyan was awarded a fellowship from the Alexander von Humboldt Foundation of Germany to conduct research at the Institute of Immunology in Kiel (Cluster for Excellence in Inflammation at Interfaces), where she advanced understanding on the healing potential of the innate immune system for cancer immunotherapy and uncovered how certain drugs commonly used to treat chronic and degenerative diseases adversely impact immune integrity. Dr. Kalyan’s primary interest and expertise are in improving the efficacy and safety of therapies targeting immune dysfunction, particularly in the context of chronic inflammatory disorders and cancer, and determining how to best harness the ability of the innate immune system to support recovery from disease.

Past events:


Past events: